About 200 reports

  • Rising incidences of chronic pain
  • Tetra Bio Pharma Pipeline
  • Chronic Pain
  • World
  • AstraZeneca PLC
  • Endo International plc
  • Pfizer Inc.
  • Key takeaways
  • Failed back syndrome
  • Chronic Pain
  • Market Size
  • Flowonix Medical, Inc.
  • Medtronic, Inc.
  • Teleflex Incorporated
  • 2.1 Preface
  • JIANGSU HENGRUI MEDICINE
  • Chronic Pain
  • Depomed, Inc.
  • Eli Lilly & Co.
  • Endo International plc
  • Pfizer Inc.
  • 2.6 Comorbidities and Complications
  • 7.2.2 Deals by Indication

Acute pain in general poses a risk of transitioning to chronic pain.

  • Chronic Pain
  • World
  • Market Size
  • Allergan plc
  • Amgen Inc.
  • Market segmentation by type

Hoffmann-La Roche RG## Stage of development PTI-## Pain Therapeutics Phase I PTI-## Pain Therapeutics Phase I Phase I Phase I Phase I Indication Pain Cancer pain Pain Moderate-to-severe chronic pain Moderate-to-severe

  • Chronic Pain
  • World
  • AstraZeneca PLC
  • Endo International plc
  • Pfizer Inc.

Chronic Pain Market Forecast ($), Japan, 2015 – 2020 The latest research from Fore Pharma, Global Chronic Pain Market and Competitive Landscape Highlights – 2016, provides comprehensive insights into Chronic Pain pipeline products,

  • Chronic Pain
  • France
  • Germany
  • Italy
  • Market Size
  • DRUGS UNDER DEVELOPMENT FOR SEVERE CHRONIC PAIN
  • APPROVED PHARMACOLOGICAL TREATMENT DRUGS FOR CHRONIC PAIN
  • Chronic Pain
  • United States
  • Egalet Corporation
  • Pfizer Inc.
  • Purdue Pharma L.P.
  • Market drivers
  • Key vendor analysis

It helps alleviate acute and chronic back pain.

  • Chronic Pain
  • Musculoskeletal Disorder
  • World
  • Demand
  • DeRoyal Industries, Inc.
  • 5.3 The US Chronic Pain Market Analysis
  • US CHRONIC PAIN MARKET 2014F-2019F (IN US$ BILLIONS)
  • Chronic Pain
  • Boston Scientific Corporation
  • Jude Medical, Inc.
  • Medtronic, Inc.
  • Nevro Corporation

Chronic Pain Market Forecast ($), UK, 2015 – 2020 The latest research from Fore Pharma, Europe Chronic Pain Market and Competitive Landscape Highlights – 2016, provides comprehensive insights into Chronic Pain pipeline products, Chronic

  • Chronic Pain
  • Europe
  • France
  • Germany
  • Market Size

Japan Chronic Pain Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Chronic Pain Treatments ##) Chronic Pain Pipeline ##) Japan Chronic Pain Epidemiology ##) Marketed Drug

  • Chronic Disease
  • Chronic Pain
  • Pathology
  • Japan
  • Market Size

Germany Chronic Pain Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Chronic Pain Treatments ##) Chronic Pain Pipeline ##) Germany Chronic Pain Epidemiology ##) Marketed

  • Chronic Disease
  • Chronic Pain
  • Pathology
  • Germany
  • Market Size

UK Chronic Pain Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Chronic Pain Treatments ##) Chronic Pain Pipeline ##) UK Chronic Pain Epidemiology ##) Marketed Drugs for

  • Chronic Disease
  • Chronic Pain
  • Pathology
  • United Kingdom
  • Market Size

Italy Chronic Pain Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Chronic Pain Treatments ##) Chronic Pain Pipeline ##) Italy Chronic Pain Epidemiology ##) Marketed Drug

  • Chronic Disease
  • Chronic Pain
  • Pathology
  • Italy
  • Market Size

France Chronic Pain Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Chronic Pain Treatments ##) Chronic Pain Pipeline ##) France Chronic Pain Epidemiology ##) Marketed Dr

  • Chronic Disease
  • Chronic Pain
  • Pathology
  • France
  • Market Size

Spain Chronic Pain Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Chronic Pain Treatments ##) Chronic Pain Pipeline ##) Spain Chronic Pain Epidemiology ##) Marketed Drug

  • Chronic Disease
  • Chronic Pain
  • Pathology
  • Spain
  • Market Size

US Chronic Pain Market and Competitive Landscape Highlights – 2016 ##) Disease Overview a) Etiology b) Pathophysiology c) Diagnosis ##) Chronic Pain Treatments ##) Chronic Pain Pipeline ##) US Chronic Pain Epidemiology ##) Marketed Drugs for

  • Chronic Disease
  • Chronic Pain
  • Pathology
  • Market Size
  • 17. Market Trends
  • 06. Introduction

Cymbalta is also approved for the treatment of generalized anxiety disorder, major depressive disorder, diabetic peripheral neuropathic pain, and chronic musculoskeletal pain.

  • Chronic Pain
  • World
  • Actavis plc
  • Eli Lilly & Co.
  • Pfizer Inc.

Abuse-Deterrent Opioids Survey KOL Interview Biomedtracker performed a ##-question survey of ## United States primary care physicians who currently treat patients with chronic pain and prescribe opioids to at least some of their patients with chronic pain to gauge

  • Ambulatory Care
  • Chronic Disease
  • Chronic Pain
  • Pathology
  • United States
  • PRODUCT PROFILE - CYMBALTA
  • 3.1 ETIOLOGY AND PATHOPHYSIOLOGY
  • Chronic Pain
  • Actavis plc
  • Daiichi Sankyo Company
  • Eli Lilly & Co.
  • Forest Laboratories, Inc.

Chronic Pain, 2016 Acute pain versus chronic pain, by type of pain Table ##-##: Types of Physical Pain Suffered from Most in Past ## Months: Acute vs.

  • Chronic Pain
  • Healthcare
  • Pain Relief
  • United States
  • Demand

Chronic Neuropathic Pain KOL Survey Biomedtracker performed a ##-question survey of ## United States neurologists who currently treat patients with chronic neuropathic pain and prescribe opioids to at least some of their patients with chronic neuropathic

  • Chronic Disease
  • Chronic Pain
  • Pathology
  • United States

Depending on the specific site affected, this can lead to chronic pain and loss of mobility and have a negative impact on quality of life.

  • Chronic Pain
  • World
  • Market Size
  • Johnson & Johnson
  • Novartis AG
  • 11.2.3 ST JUDE MEDICAL, INC.
  • Your view on Percent Contribution ($Value) : Global Neuromodulation Spinal Cord Stimulation Market, by Application
  • Chronic Pain
  • World
  • Boston Scientific Corporation
  • Jude Medical, Inc.
  • Medtronic, Inc.
  • PRODUCT PROFILE - CYMBALTA
  • 3 Disease Overview
  • Chronic Pain
  • Daiichi Sankyo Company
  • Pfizer Inc.
  • Theravance, Inc.
  • Tonix Pharmaceuticals Holding Corp.

Opioids and Chronic Neuropathic Pain Management KOL Interview Biomedtracker interviewed a neurologist based in the United States who currently treats over ## patients with chronic neuropathic pain per year to determine his current treatment practices for indications incl

  • Chronic Disease
  • Chronic Pain
  • Pathology
  • United States
  • Vendor landscape
  • Introduction

CYMBALTA IS AN SNRI INDICATED FOR CHRONIC MUSCULOSKELETAL PAIN ASSOCIATED WITH OSTEOARTHRITIS.

  • Chronic Pain
  • World
  • Market Size
  • Novartis AG
  • Pfizer Inc.
  • AUSTRALIA KNEE OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS PATIENT
  • MARKET OVERVIEW: AUSTRALIA

MARKET OVERVIEW: AUSTRALIA ##. ## INTRODUCTION The most common cause of chronic knee pain and disability is arthritis.

  • Chronic Pain
  • Asia
  • Smith & Nephew Plc
  • Stryker Corporation
  • Zimmer Biomet Holdings, Inc.
  • Chronic Pain
  • Types of Chronic Pain
  • Chronic Pain
  • United States
  • Egalet Corporation
  • Pfizer Inc.
  • Zogenix, Inc.

Chronic prostatitis ##. ##. ##.

  • Chronic Disease
  • Chronic Pain
  • Pathology
  • World
  • Forecast